Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Clofarabine Followed By Lenalidomide for High-Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia

This study has been completed.
Sponsor:
Collaborator:
Celgene Corporation
Information provided by:
National Institutes of Health Clinical Center (CC)
ClinicalTrials.gov Identifier:
NCT01629082
First received: June 22, 2012
Last updated: August 31, 2016
Last verified: June 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: October 2015
  Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)